1. Home
  2. ABVC vs GRML Comparison

ABVC vs GRML Comparison

Compare ABVC & GRML Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ABVC BioPharma Inc.

ABVC

ABVC BioPharma Inc.

HOLD

Current Price

$1.04

Market Cap

34.6M

Sector

Health Care

ML Signal

HOLD

Logo Greenland Mines Ltd. Common Stock

GRML

Greenland Mines Ltd. Common Stock

N/A

Current Price

$0.20

Market Cap

34.9M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
ABVC
GRML
Founded
2015
N/A
Country
United States
United States
Employees
N/A
5
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
34.6M
34.9M
IPO Year
2009
2022

Fundamental Metrics

Financial Performance
Metric
ABVC
GRML
Price
$1.04
$0.20
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
149.6K
7.7M
Earning Date
05-14-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
7.14
N/A
EPS
N/A
N/A
Revenue
$509,589.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.88
$0.16
52 Week High
$3.39
$0.55

Technical Indicators

Market Signals
Indicator
ABVC
GRML
Relative Strength Index (RSI) 37.18 44.53
Support Level $0.96 $0.16
Resistance Level $1.15 $0.30
Average True Range (ATR) 0.10 0.04
MACD -0.03 0.00
Stochastic Oscillator 14.29 31.13

Price Performance

Historical Comparison
ABVC
GRML

About ABVC ABVC BioPharma Inc.

ABVC BioPharma Inc is a clinical stage biopharmaceutical company focused on development of new drugs and medical devices, all of which are derived from plants. It currently has six drugs and three medical devices in development. The firm specializes in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes. Its products include: Vitargus - ABV-1701, ABV-2001, ABV-2002, MDD ABV-1504, ADHD ABV-1505, ADHD ABV-1601, ABV-1501, ABV-1702, and ABV-1703.

About GRML Greenland Mines Ltd. Common Stock

Greenland Mines Ltd develops essential medicines for the treatment of chronic diseases - cancer, cardiovascular, and neurodegenerative disorders. The Company operates as a single reporting segment focused on developing essential medicines for these chronic diseases. The Company has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and proprietary patented technologies involving melanocortin receptor-binding molecules and a gene therapy platform that introduces a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases.

Share on Social Networks: